Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses [CMS-4180-P]” published in the Federal Register on November 30, 2018.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments in response to Centers for Medicare & Medicaid Services’ (CMS) Advanced Notice of Proposed Rulemaking (ANPRM) on the Medicare Program; International Pricing Index Model for Medicare Part B Drugs; [CMS5528-ANPRM].
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule “Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program of All-Inclusive Care for the Elderly (PACE), Medicaid Fee-for-Service and Medicaid Managed Care Programs for Years 2020 and 2021 [CMS-4185-P]” published in the Federal Register on November 1, 2018.
The Academy of Managed Care Pharmacy (AMCP) is pleased provide comments to the Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency [CMS-4187-P]” published in the Federal Register on October 18, 2018.
On November 26, The Centers for Medicare and Medicaid Services (CMS) issued a new proposed rule outlining potential policies that are intended to lower the cost of prescription drugs through tools that allow prescription drug plans to negotiate prices and by improving access to costly drugs through reduction of out-of-pocket costs for beneficiaries.
On Nov 1, The Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that updates Medicare Advantage (MA or Part C) and the Medicare Prescription Drug Benefit Program (Part D).
On November 1, 2018, the Centers for Medicare & Medicaid Services (CMS) finalized its rule for the 2019 Physician Fee Schedule (PFS) and the Quality Payment Program (QPP).
On October 30, 2018, the Centers for Medicare and Medicaid Services (CMS) published an Advanced Notice of Proposed Rulemaking (ANPRM) for a potential International Pricing Index (IPI) Model for Medicare Part B Drugs.
On October 18, 2018, the Centers for Medicare & Medicaid Services (CMS) issued a new proposed rule entitled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Facilitating Competition and Innovation in the Biological Products Marketplace; Public Hearing; Request for Comments” as published in the Federal Register on July 25, 2018.
The Academy of Managed Care Pharmacy (AMCP) thanks Congress for its dedication to combatting the opioid epidemic. The importance of H.R. 6 increases as the number of preliminary CDC reported overdose deaths rise (72,000 overdose deaths in 2017). Both pieces of legislation passed by the House and Senate will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and increase education initiatives for patients and providers.
AMCP supports the concept of collaborative drug therapy management (CDTM), a formal partnership between a pharmacist and a prescriber that allows the pharmacist to manage a patient’s drug therapy. CDTM, also referred to as collaborative practice, allows pharmacists to use their unique skills and abilities to complement other types of care provided by collaborating professionals to optimize patient outcomes.
